# A Study of JS026 and JS026 Together With JS016 for Treatment of COVID-19

> **NCT05167279** · PHASE1 · COMPLETED · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 48 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** JS026/placebo
- **BIOLOGICAL:** JS016/placebo

## Key facts

- **NCT ID:** NCT05167279
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-16
- **Primary completion:** 2022-12-08
- **Final completion:** 2022-12-08
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05167279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05167279, "A Study of JS026 and JS026 Together With JS016 for Treatment of COVID-19". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT05167279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*